How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vertebroplasty & Kyphoplasty Market
- By Procedure Type: Vertebroplasty, Kyphoplasty
- By Material Type: Polymethylmethacrylate (PMMA) Cement, Calcium Phosphate Cement, Bioactive Glass Cement
- By Application Indication: Osteoporotic Vertebral Compression Fractures, Metastatic Spinal Tumors, Multiple Myeloma, Traumatic Vertebral Fractures
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
- By Guidance Technology: Fluoroscopy-Guided, CT-Guided, MRI-Guided
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Vertebroplasty leads By Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Vertebroplasty & Kyphoplasty Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Procedure Type 2
Material Type 3
Application Indication 4
End User 3
Guidance Technology 3
Companies profiled
Medtronic
Stryker Corporation
DePuy Synthes (Johnson & Johnson)
Zimmer Biomet
Globus Medical
Siemens Healthineers
Carestream Health
Alphatec Holdings Inc.
RTI Surgical
K2M Group Holdings
Inc. (acquired by Stryker)
NuVasive Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →DePuy Synthes (Johnson & Johnson)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Zimmer Biomet
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Globus Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Carestream Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Alphatec Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →RTI Surgical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →K2M Group Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (acquired by Stryker)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →NuVasive Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Orthofix International N.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →B. Braun Melsungen AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cook Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Mizuho OSI
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,135M by 2033 · 10.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Vertebroplasty79.9
- Kyphoplasty20.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$600.3M → $1,259M · 9.7%
Europe$418.4M → $918.2M · 10.3%
Asia Pacific$382.0M → $799.0M · 9.7%
Latin America$236.5M → $501.9M · 9.9%
Middle East and Africa$181.9M → $373.5M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.772026
10.782027
10.782028
10.812029
10.822030
10.822031
10.842032
10.852033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic16.5
- Stryker Corporation21.1
- DePuy Synthes (Johnson & Johnson)9.3
- Zimmer Biomet7.6
- Globus Medical8.7
- Siemens Healthineers8.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Type9.2%
Material Type26.7%
Application Indication18.8%
End User22.3%
Guidance Technology23.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe23.8
- Asia Pacific20.7
- Latin America13.0
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 85 | 76 | 74 | 91 | 74 | 94 | 82 |
| Stryker Corporation | 91 | 90 | 77 | 72 | 88 | 72 | 82 |
| DePuy Synthes (Johnson & Johnson) | 71 | 81 | 71 | 67 | 72 | 71 | 72 |
| Zimmer Biomet | 76 | 79 | 58 | 79 | 68 | 68 | 71 |
| Globus Medical | 55 | 51 | 77 | 53 | 77 | 69 | 64 |
| Siemens Healthineers | 46 | 63 | 58 | 54 | 68 | 59 | 58 |
| Carestream Health | 45 | 45 | 57 | 60 | 59 | 41 | 51 |
| Alphatec Holdings Inc. | 43 | 55 | 39 | 38 | 56 | 46 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Stryker Corporation
- DePuy Synthes (Johnson & Johnson)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Stryker Corporation | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| DePuy Synthes (Johnson & Johnson) | ◐ | ✓ | − | − | − | ✓ |
| Zimmer Biomet | ◐ | ◐ | − | ◐ | ✓ | − |
| Globus Medical | − | − | ✓ | − | ◐ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Carestream Health | − | ◐ | ◐ | − | − | − |
| Alphatec Holdings Inc. | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic82
2Stryker Corporation82
3DePuy Synthes (Johnson & Johnson)72
4Zimmer Biomet71
5Globus Medical64
6Siemens Healthineers58
7Carestream Health51
8Alphatec Holdings Inc.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicStryker Corporation
Challenger2
Strong scale, closing on the leaders.
DePuy Synthes (Johnson & Johnson)Zimmer Biomet
Contender2
Focused players with pockets of strength.
Globus MedicalSiemens Healthineers
Niche2
Specialists in a single segment or region.
Carestream HealthAlphatec Holdings Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Procedure Type in North America, then scale across Vertebroplasty & Kyphoplasty Market — a $302M beachhead inside a $5.51B market.
Beachhead (SOM)$302Mobtainable near-term
Serviceable (SAM)$1.91Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Vertebroplasty
Best fit — highest urgency & budget in Procedure Type.
Economic buyer79 fit
Kyphoplasty
Strong fit — clear ROI and a fast path to value.
End user65 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vertebroplasty & Kyphoplasty Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation14%
Closed-won7%
$14.2KCAC
$52KLTV
3.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Vertebroplasty & Kyphoplasty Market is a durable-growth opportunity — $5.03B by 2033, compounding at 7.7%.
TAM · 2025$2.77Btoday
TAM · 2033$5.03Bforecast
CAGR7.7%2027–2033
Cumulative$34.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.03BTotal addressable market
SAM$1.93BServiceable available market
SOM$389MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.7% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.03BLarge & growingTAM by 2033 at 7.7% CAGR
$1.93BServiceable nowreachable with today’s model
$389MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.92BBear5.0% CAGR
$5.03BBase7.7% CAGR
$6.44BBull10.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Vertebroplasty & Kyphoplasty Market — a $6.62B market by 2033. Plan: grow share from 10.0% to 16.2%.
Market size · 2033$6.62Btotal addressable
Market CAGR8.3%2027–2033
Target share16.2%from 10.0% today
Revenue ambition$1.07Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 16.2% | On track |
| Revenue | $666M | $1.07B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 36.6% | 38.4% | Ahead |
| Customer retention | 84.5% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material Type capability
A defensible second engine — invest in Material Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $110M capacity & capability investment
- Greenlight bolt-on M&A in Material Type
- Authorise North America expansion plan
- Fund R&D program for Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Vertebroplasty & Kyphoplasty Market conversation — a $5.30B market you can size, segment and defend in minutes.
Market size · 2033$5.30Btotal opportunity
Growth8.6%CAGR to 2033
Addressable buyers1,356+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Type
Goal Grow share in Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 3 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
MedtronicStryker CorporationDePuy Synthes (Johnson & Johnson)Zimmer BiometGlobus MedicalSiemens HealthineersCarestream HealthAlphatec Holdings Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vertebroplasty & Kyphoplasty Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Vertebroplasty & Kyphoplasty Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Vertebroplasty and Kyphoplasty Needles Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportVertebrobasilar Insufficiency Treatment Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportVertebrectomy Prosthesis Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportVertebral Osteotome Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportVertebral Compression Fracture (VCF) Devices Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportVertebral Balloon Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportVertebral Augmentation System Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportVertebral Augmentation Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportVersatile Microcentrifuge Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportVero Cell Rabies Vaccines for Human Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportVernal Keratoconjunctivitis Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportVermox Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.